Repros jumps on Phase III Androxal data

Repros Therapeutics Inc. (NASDAQ:RPRX) gained $6.97 (76%) to $16.10 on Thursday after once-daily oral Androxal enclomiphene met the co-primary endpoints in 151 men in the intent-to-treat (ITT) populat...